EHMT1 antibody

Catalog No. ABIN969480

Product Details anti-EHMT1 Antibody

Target: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EHMT1 antibody is un-conjugated

Application: ELISA

Purpose: GLP Antibody

Purification: Ascitic fluid

Immunogen: Purified recombinant fragment of GLP expressed in E. Coli.

Clone: 1B7B4

Isotype: IgG1

Application Details

Application Notes: ELISA: 1/10000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

References for anti-EHMT1 antibody (ABIN969480)

De León, Crutchlow, Ham, Stoffers: "Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus." in: The international journal of biochemistry & cell biology, Vol. 38, Issue 5-6, pp. 845-59, (2006) (PubMed).

Young: "Inhibition of glucagon secretion." in: Advances in pharmacology (San Diego, Calif.), Vol. 52, pp. 151-71, (2006) (PubMed).

Target Details for EHMT1

Target: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Alternative Name: GLP (EHMT1 Products)

Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L cells in response to ingested nutrients. The closely related peptides glucagon-like peptide (GLP-1) and glucagon have opposing effects on blood glucose. GLP-1 induces glucose-dependent insulin secretion in the pancreas, while glucagon stimulates gluconeogenesis and glycogenolysis in the liver. Glucagon is processed from a large precursor, proglucagon, in a tissue-specific manner in pancreatic alpha-cells. The identification of a hybrid peptide acting as both a GLP-1 agonist and a glucagon antagonist would provide a novel approach for the treatment of type 2 diabetes.

Gene ID: 79813

UniProt: Q9H9B1